29 July 2024 - trading update
The AIM-listed pharmaceutical group has announced a trading statement for the six months to 30 June and this has revealed that revenues were 2.8% ahead of H1 2023 at £84.8m. Net debt has continued to decline during the period and this is expected to continue in the second half due to the group's strong cash generation. Revenues are also expected to build in the second half of the year and the group therefore expects profits for the full year to be similar to 2023 as previously indicated. The share price has . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
